Theravance Biopharma (NASDAQ:TBPH) Sets New 1-Year High - Here's Why

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $11.88 and last traded at $11.65, with a volume of 85478 shares. The stock had previously closed at $11.65.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Saturday, July 12th. Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Finally, BTIG Research upped their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Theravance Biopharma presently has an average rating of "Moderate Buy" and an average price target of $16.60.

Theravance Biopharma Stock Performance

The company has a 50 day moving average of $10.47 and a 200 day moving average of $9.67. The stock has a market capitalization of $567.50 million, a price-to-earnings ratio of -9.62 and a beta of -0.02.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. On average, equities analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock in a transaction on Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at approximately $3,723,596.02. The trade was a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders sold 44,000 shares of company stock worth $491,800. 6.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ballentine Partners LLC grew its holdings in Theravance Biopharma by 9.3% in the second quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company's stock valued at $158,000 after purchasing an additional 1,221 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in Theravance Biopharma during the second quarter worth approximately $264,000. Rhumbline Advisers boosted its holdings in Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after acquiring an additional 2,293 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after purchasing an additional 174,451 shares during the period. Finally, Jane Street Group LLC increased its position in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock worth $1,258,000 after acquiring an additional 88,540 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.